The manufacturer of a prescription omega-3 fish oil product has announced preliminary results of a trial showing significant reduction in cardiovascular events using a high-dose formulation. The study (REDUCE-IT) enrolled over 8,000 patients at elevated risk of cardiovascular events (patients had raised triglyceride levels plus either a previous cardiovascular event or diabetes with one additional risk factor). Subjects were all given a statin, and were randomized to receive either placebo or 4 g/day of eicosapentaenoic acid (EPA). After median follow-up of almost 5 years, there was an approximately 25% relative risk reduction in first occurrence of a major adverse cardiovascular event (death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. The high-dose was also shown to be well tolerated compared to placebo. More details of the trial results are expected at the American Heart Association (AHA) Scientific Sessions in November 2018.
For more information about the REDUCE-IT trial, click here.
Additional reporting from Medscape, click here.
Additional information about Omega-3-Ethyl Esters can be found in the Top 300 Pharmacy Drug Cards or the Top 100 Nonprescription Drug Cards. If you or your institution subscribes to AccessPharmacy, use or create your MyAccess Profile to sign-in to the Flash Card section. If your institution does not provide access, ask your medical librarian about subscribing.
For a chance to win GREAT prizes and learn more about medications in the Top 300, check out the Drug Card Scavenger Hunt page on AccessPharmacy. Follow us to receive email alerts when new Drug of the Week and Drug Card Scavenger Hunt updates are posted.